Navamedic acquires dne pharma for Nkr225m, entering addiction treatment market
From Yahoo Finance: 2025-06-24 07:19:00
Navamedic has acquired dne pharma for Nkr225m, marking its entry into addiction treatment. The deal includes initial Nkr185m payment and Nkr40m contingent on sales. Products like Ventizolve, Levopidon, and Metadon Dne will be added to their portfolio.
The acquisition is expected to boost Navamedic’s revenue, with dne pharma reporting net sales of Nkr62m in 2024. It is projected to contribute Nkr25m in EBITDA annually. The integration process will involve merging new products into Navamedic’s commercial platform, leading to synergies in logistics and geographical presence.
To finance the acquisition, Navamedic secured Nkr110m in new debt funding and a bridge loan. Finalization of the deal is subject to approval at a general meeting on 14 July 2025. If not approved, dne pharma will receive Nkr5m as termination fee.